T0	Outcomes 0 40	Safety, tolerability, and immunogenicity
T1	Outcomes 519 556	compared immunity and safety profiles
T2	Outcomes 614 622	placebo.
T3	Outcomes 623 637	Immunogenicity
T4	Outcomes 652 802	using VZV interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay and VZV glycoprotein enzyme-linked immunosorbent antibody (gpELISA) assay.
T5	Outcomes 803 828	Adverse experiences (AEs)
T6	Outcomes 886 893	RESULTS
T7	Outcomes 897 920	serious vaccine-related
T8	Outcomes 925 934	occurred.
T9	Outcomes 935 1040	VZV IFN-γ ELISPOT geometric mean count (GMC) of spot-forming cells per 10(6) peripheral blood mononuclear
T10	Outcomes 1190 1200	postdose 2
T11	Outcomes 1232 1244	respectively
T12	Outcomes 1304 1329	The peak ELISPOT response
T13	Outcomes 1362 1367	dose.
T14	Outcomes 1368 1401	The gpELISA geometric mean titers
T15	Outcomes 1480 1490	each dose.
T16	Outcomes 1491 1540	Correlation between the IFN-γ ELISPOT and gpELISA
T17	Outcomes 1577 1617	generally well-tolerated and immunogenic
T18	Outcomes 1663 1676	was generally
T19	Outcomes 1701 1713	VZV-specific